Is the GAIN Act a turning point in new antibiotic discovery? Journal Articles

abstract

• The United States GAIN (Generating Antibiotic Incentives Now) Act is a call to action for new antibiotic discovery and development that arises from a ground swell of concern over declining activity in this therapeutic area in the pharmaceutical sector. The GAIN Act aims to provide economic incentives for antibiotic drug discovery in the form of market exclusivity and accelerated drug approval processes. The legislation comes on the heels of nearly two decades of failure using the tools of modern drug discovery to find new antibiotic drugs. The lessons of failure are examined herein as are the prospects for a renewed effort in antibiotic drug discovery and development stimulated by new investments in both the public and private sector.

authors

• Brown, Eric

status

• published 

publication date

• March 2013

has subject area

• 0605 Microbiology (FoR)
• 0707 Veterinary Sciences (FoR)
• 1108 Medical Microbiology (FoR)
• Anti-Bacterial Agents (MeSH)
• Drug Approval (MeSH)
• Drug Discovery (MeSH)
• Drug Industry (MeSH)
• Drug Resistance, Microbial (MeSH)
• Humans (MeSH)
• Legislation, Drug (MeSH)
• Microbiology (Science Metrix)
• Private Sector (MeSH)
• United States (MeSH)

published in

• Canadian Journal of Microbiology  Journal

keywords

• Anti-Bacterial Agents
• Drug Approval
• Drug Discovery
• Drug Industry
• Drug Resistance, Microbial
• Humans
• Legislation, Drug
• Private Sector
• United States

Digital Object Identifier (DOI)

• 10.1139/cjm-2013-0089

PubMed ID

• 23540332

start page

• 153

end page

• 156

volume

• 59

issue

• 3